Phaseline

Targets › TXK

TXK (Tyrosine-protein kinase TXK): drug programs, companies and trials

1 program from 1 company in 11 trials: 6 Phase 3, 5 Phase 2; Immunology, Metabolic and endocrine; next expected readout Dec 2026.

Non-receptor tyrosine kinase that plays a redundant role with ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. (UniProt, P42681)

Open in Phaseline: the race on TXK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerRitlecitinib
Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor
JAK3, ITK, BMX, TEC, TXKPhase 3Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata …Dec 2026

Conditions

Severe Alopecia Areata (2) Vitiligo (2) Alopecia Areata (2) Stable Nonsegmental Vitiligo (1) Hidradenitis Suppurativa (1) Chronic Spontaneous Urticaria (1) Keloid (1) Diabetes Mellitus, Type 1 (1)

Modalities

small molecule (1)

Companies

Pfizer (1)

Related targets

JAK3 (1) ITK (1) BMX (1) TEC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.